BRD2 and endometrial cancer: Although prior studies have demonstrated that FSH can induce growth in distinct endometrial cancer cell lines using hormone concentrations ranging from 100 – 3000 U/L of recombinant hormone (47), we were unable to detect any changes in cell viability in response to FSH in the Ishikawa cell line.